

# [NeoGenomics launches AML Express NGS assay](#)

written by CAP TODAY  
October 9, 2024

Oct. 9, 2024—[NeoGenomics](#) has launched its AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia. The panel includes an extensive list of genes selected for their clinical relevance in AML, covering DNA and RNA alterations, and is intended to be used in conjunction with clinical features and other laboratory results. The turnaround time is three to four days.



©2026 CAP TODAY, all rights reserved.